Belatacept and basiliximab diminish human antiporcine xenoreactivity and synergize to inhibit alloimmunity

Transplantation

Volumn 85, Issue 1, 2008, Pages 118-124

  Emamaullee, Juliet A ^a   Merani, Shaheed ^a   Larsen, Christian P ^b   Shapiro, A M James ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Immunosuppression; Induction therapy; Xenotransplantation

Indexed keywords

BASILIXIMAB; BELATACEPT;

ALLOIMMUNITY; ANIMAL CELL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, HETEROPHILE; CELLS, CULTURED; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 38149028526     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000296832.92128.94     Document Type: Article

References (15)

1. Statistical Data. Richmond, VA: U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network; 2005.
2. Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci 2004; 9: 411.
3. Nanji SA, Shapiro AM. Islet transplantation in patients with diabetes mellitus: Choice of immunosuppression. BioDrugs 2004; 18: 315.
4. Ryan EA, Paty BW, Senior PA, Shapiro AM. Risks and side effects of islet transplantation. Curr Diab Rep 2004; 4: 304.
5. Molinari M, Al-Saif F, Ryan EA, et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: Report of two cases. Am J Transplant 2005; 5: 2799.
6. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
7. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
8. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
9. Tallarida RJ. Drug synergism: Its detection and applications. J Pharmacol Exp Ther 2001; 298: 865.
10. Lee RS, Yamada K, Womer KL, et al. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human antiporcine T cell responses. J Immunol 2000; 164: 3434.
11. Vaughan AN, Malde P, Rogers NJ, et al. Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7. J Immunol 2000; 165: 3175.
12. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
13. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: A randomised, double blind, placebo controlled, dose ranging trial. Gut 2006; 55: 1568.
14. Kovarik JM, Pescovitz MD, Sollinger HW, et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 2001; 15: 123.
15. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411.